RealTime Software Solutions Announces Acquisition of Devana Solutions
RealTime Software Solutions has announced its acquisition of Devana Solutions, an SaaS provider specializing in clinical trial workflow and analytics solutions.
By integrating Devana's solutions into RealTime's Site Operations Management System (SOMS), clinical research organizations will be able to access a suite of capabilities that bridge centralized operations with site-based clinical teams. The combination of these solutions establishes connectivity between Devana's business development and data analytics platform and RealTime's suite of products that includes CTMS, eRegulatory solutions, eSource, eConsent, payments, texting solutions, the MyStudyManager Participant Portal, and other eClinical solutions and services.
Originally designed to address the operational gap before participant recruitment, screening and CTMS-managed clinical workflows, Devana's PROPEL products automate pipeline management and trial startup workflows while capturing timing and performance metrics for analysis and action.
Reference
RealTime Software Solutions Strengthens its Position in the Clinical Research Industry with the Acquisition of Devana Solutions. (2023, July 6). Cision PR Newswire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
